At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,499 enrolled
Drug / intervention
daily TDF/FTC +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chemoprophylaxis for HIV Prevention in Men
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Apr 10, 2007·Updated Nov 2, 2021
In Brief
A Phase 3 clinical trial evaluating daily TDF/FTC and Placebo for HIV Infections. Completed, enrolled 2,499 participants across 11 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually transmitted infections (STIs).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesBrazil, Ecuador, Peru, South Africa, Thailand, United States
CollaboratorsBill and Melinda Gates Foundation
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartJun 2007
Primary CompletionFeb 2014
TodayJul 2026
First PostedApr 10, 2007
Enrollment StartJun 1, 2007
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 19.2 years ago
Interventions
daily TDF/FTCdrug
daily oral medication
Placebodrug
daily oral medication